Cardiovascular drugs that increase the risk of new-onset diabetes

American Heart Journal

Volumn 167, Issue 4, 2014, Pages 421-428

  Ong, Kwok Leung ^a,b   Barter, Philip J ^a,b   Waters, David D ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVINOLIN; NEBIVOLOL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROPRANOLOL; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE THERAPY; BODY MASS; DIABETES MELLITUS; ELEVATED BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MYOPATHY; NEW ONSET DIABETES; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 84897031074     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.12.025     Document Type: Review

References (67)

1. International Diabetes Federation IDF diabetes atlas update http://www.idf.org/diabetesatlas/5e/Update2012 2012 Accessed September, 2013
2. M.K. Ali, K.M. Bullard, and J.B. Saaddine et al. Achievement of goals in U.S. diabetes care, 1999-2010 N Engl J Med 368 2013 1613 1624
3. K.L. Ong, M.A. Allison, and B.M. Cheung et al. Trends in C-reactive protein levels in US adults from 1999 to 2010 Am J Epidemiol 177 2013 1430 1442
4. S.M. Grundy Pre-diabetes, metabolic syndrome, and cardiovascular risk J Am Coll Cardiol 59 2012 635 643
5. J.P. Reis, C.M. Loria, and P.D. Sorlie et al. Lifestyle factors and risk for new-onset diabetes: a population-based cohort study Ann Intern Med 155 2011 292 299
6. N. Brown, J. Critchley, and P. Bogowicz et al. Risk scores based on self-reported or available clinical data to detect undiagnosed type 2 diabetes: a systematic review Diabetes Res Clin Pract 98 2012 369 385
7. P.W. Wilson, J.B. Meigs, and L. Sullivan et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study Arch Intern Med 167 2007 1068 1074
8. N. Sattar, D. Preiss, and H.M. Murray et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
9. D.D. Waters, J.E. Ho, and D.A. DeMicco et al. Predictors of new-onset diabetes in patients treated with atorvastatin. Results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
10. D. Preiss, S.R. Seshasai, and P. Welsh et al. Risk of incident diabetes with intensive-dose compared to moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
11. D.D. Waters, J.E. Ho, and S.M. Boekholdt et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes J Am Coll Cardiol 61 2013 148 152
12. P.M. Ridker, A. Pradhan, and J.G. MacFadyen et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
13. K.K. Koh, M.J. Quon, and S.H. Han et al. Atorvastatin causes insulin resistance and increased ambient glycemia in hyperglycemic patients J Am Coll Cardiol 55 2010 1209 1216
14. R.R. Holman, S. Paul, and A. Farmer et al. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomized controlled trial Diabetalogia 52 2009 50 59
15. C.B. Newman, M. Szarek, and H.M. Colhoun et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS) Diab Vasc Dis Res 5 2008 177 183
16. R.H. Knopp, M. d'Emden, and J.G. Smilde et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes Diabetes Care 29 2006 1478 1485
17. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
18. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 686
19. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
20. J. Shepherd, P. Barter, and R. Carmena et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes Diabetes Care 29 2006 1220 1226
21. J.D. Colbert, and J.A. Stone Statin use and the risk of incident diabetes mellitus: a review of the literature Can J Cardiol 28 2012 581 589
22. M. Ishikawa, F. Okajima, and N. Inoue et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells J Atheroscler Thromb 13 2006 329 335
23. M. Kanda, K. Satoh, and K. Ichihara Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin Biol Pharm Bull 26 2003 1681 1684
24. R.P. Narayanan, M. Gittins, and K.W. Siddals et al. Atorvastatin administration is associated with dose-related changes in IGF bioavailability Eur J Endocrinol 168 2013 543 548
25. J.E. Mallinson, D. Constantin-Teodosiu, and J. Sidaway et al. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy J Physiol 587 pt 1 2009 219 230
26. V. Sazonov, D. Maccubbin, and C.M. Sisk et al. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose Int J Clin Pract 67 2013 297 302
27. Armitage J, on behalf of the HPS2-THRIVE Collaborative Group. HPS2-THRIVE: randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Presented at the American College of Cardiology Annual Scientific Sessions, San Francisco, CA, March 9, 2013.
28. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
29. M.G. Goldner, H. Zarowitz, and S. Akgun Hyperglycemia and glucosuria due to thiazide derivatives administered in diabetes mellitus N Engl J Med 262 1960 403 405
30. F.W. Wolff, W.W. Parmley, and K. White et al. Drug-induced diabetes JAMA 185 1963 568 574
31. A.V. Chobanian, G.L. Bakris, and H.R. Black et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
32. R.M. Cooper-DeHoff, M.A. Pacanowski, and C.J. Pepine Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum J Am Coll Cardiol 53 5 Suppl 2009 S28 S34
33. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
34. W.J. Elliott, and P.M. Meyer Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 369 2007 201 207
35. J.I. Barzilay, B.R. Davis, and J.A. Cutler et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 166 2006 2191 2201
36. J.I. Barzilay, B.R. Davis, and S.L. Pressel et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study Circ Cardiovasc Qual Outcomes 5 2012 153 162
37. J.B. Kostis, A.C. Wilson, and R.S. Freudenberger et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes Am J Cardiol 95 2005 29 35
38. L.E. Eberly, J.D. Cohen, and R. Prineas et al. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience Diabetes Care 26 2003 848 854
39. T. Almgren, L. Wilhelmsen, and O. Samuelsson et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up J Hypertens 25 2007 1311 1317
40. K. Dunder, L. Lind, and B. Zethelius et al. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study BMJ 326 2003 681
41. A.J. Zillich, J. Garg, and S. Basu et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review Hypertension 48 2006 219 224
42. T. Shafi, L.J. Appel, and E.R. Miller 3rd et al. Changes in serum potassium mediate thiazide-induced diabetes Hypertension 52 2008 1022 1029
43. S.M. Smith, S.D. Anderson, and S. Wen et al. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study Pharmacotherapy 29 2009 1157 1165
44. B.L. Carter, P.T. Einhorn, and M. Brands et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute Hypertension 52 2008 30 36
45. C. Meisinger, D. Stöckl, and I.M. Rückert et al. Serum potassium is associated with prediabetes and newly diagnosed diabetes in hypertensive adults from the general population: the KORA F4-study Diabetologia 56 2013 484 491
46. A.J. Stears, S.H. Woods, and M.M. Watts et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension Hypertension 59 2012 934 942
47. J.E. Carlsen, L. Køber, and C. Torp-Pedersen et al. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects BMJ 300 1990 975 978
48. S. Mayor NICE removes beta blockers as first line treatment for hypertension BMJ 333 2006 8
49. S. Bangalore, F.H. Messerli, and J.B. Kostis et al. Cardiovascular protection using beta-blockers: a critical review of the evidence J Am Coll Cardiol 50 2007 562 572
50. S. Bangalore, S. Parkar, and E. Grossman et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus Am J Cardiol 100 2007 1254 1262
51. O. Vardeny, H. Uno, and E. Braunwald et al. Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease Am J Cardiol 107 2011 1705 1709
52. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 BMJ 317 1998 713 720
53. G.L. Bakris, V. Fonseca, and R.E. Katholi et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial JAMA 292 2004 2227 2236
54. T. Pollare, H. Lithell, and I. Selinus et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients BMJ 298 1989 1152 1157
55. C. Smith, and M. Teitler Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors Cardiovasc Drugs Ther 13 1999 123 126
56. S. Jacob, K. Rett, and E.J. Henriksen Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 11 1998 1258 1265
57. P. Lee, A.P. Kengne, and J.R. Greenfield et al. Metabolic sequelae of β-blocker therapy: weighing in on the obesity epidemic? Int J Obes (Lond) 35 2011 1395 1403
58. J. Tuomilehto, J. Lindström, and J.G. Eriksson et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
59. W.C. Knowler, E. Barrett-Connor, and S.E. Fowler et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
60. K. Yamaoka, and T. Tango Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials Diabetes Care 28 2005 2780 2786
61. J. Lindström, P. Ilanne-Parikka, and M. Peltonen et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study Lancet 368 2006 1673 1679
62. D. Preiss, and N. Sattar Pharmacotherapy: statins and new-onset diabetes - the important questions Nat Rev Cardiol 9 2012 190 192
63. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 2013 S11 S66
64. G. Mancia, R. Fagard, and K. Narkiewicz et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension J Hypertens 31 2013 1925 1938
65. DREAM Trial investigators J. Bosch, and S. Yusuf et al. Effect of ramipril on the incidence of diabetes N Engl J Med 355 2006 1551 1562
66. NAVIGATOR Study Group J.J. McMurray, and R.R. Holman et al. Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
67. P. Deedwania, P. Barter, and R. Carmena et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study Lancet 368 2006 919 928